-
1
المؤلفون: Klaas van der Linde, Michelle S G Sikkens, Yvonne J B van Megen, M. W. M. D. Lutgens, Joanne P J Bloemsaat-Minekus, Corinne M Stoop, Andrea Van Der Meulen, Halil Akol, Marieke Pierik, Johan Kuijvenhoven, Ids J. Klompmaker, Gerard Dijkstra
المساهمون: Interne Geneeskunde, MUMC+: MA Maag Darm Lever (9), RS: NUTRIM - R2 - Liver and digestive health
المصدر: Crohn's & Colitis 360, 4(3):001. Oxford University Press
Crohn's & Colitis 360, 4(3). OXFORD UNIV PRESSمصطلحات موضوعية: medicine.medical_specialty, business.industry, Gastroenterology, Biosimilar, EFFICACY, medicine.disease, THERAPY, Inflammatory bowel disease, CROHNS-DISEASE, Infliximab, quality of life, Quality of life, inflammatory bowel disease, Internal medicine, END-POINTS, medicine, biosimilar, INHIBITORS, infliximab, business, medicine.drug
وصف الملف: application/pdf
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dfe906b4eebf52832318eaa05e6cf380
https://doi.org/10.1093/crocol/otab001 -
2
المؤلفون: Anne S. Strik, Yvonne J B van Megen, Michael T. Nurmohamed, Wim van de Vrie, Theo Rispens, Joanne P J Bloemsaat-Minekus, Peter Bossuyt, Alexander Bodelier, Geert R. D'Haens
المساهمون: Gastroenterology and hepatology, Rheumatology, ACS - Atherosclerosis & ischemic syndromes, AII - Inflammatory diseases, AGEM - Digestive immunity, Gastroenterology and Hepatology, Graduate School, Landsteiner Laboratory
المصدر: SECURE study group 2018, ' Serum concentrations after switching from originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease (SECURE) : an open-label, multicentre, phase 4 non-inferiority trial ', The Lancet Gastroenterology and Hepatology, vol. 3, no. 6, pp. 404-412 . https://doi.org/10.1016/S2468-1253(18)30082-7
The Lancet Gastroenterology and Hepatology, 3(6), 404-412. Elsevier Ltd
lancet. Gastroenterology & hepatology, 3(6), 404-412. Elsevier Limitedمصطلحات موضوعية: Adult, Male, medicine.medical_specialty, Population, Equivalence Trials as Topic, Inflammatory bowel disease, 03 medical and health sciences, 0302 clinical medicine, Crohn Disease, Gastrointestinal Agents, Internal medicine, medicine, Clinical endpoint, Humans, Prospective Studies, education, Adverse effect, Biosimilar Pharmaceuticals, Aged, Aged, 80 and over, education.field_of_study, Gastrointestinal agent, Hepatology, business.industry, Remission Induction, Gastroenterology, Antibodies, Monoclonal, Middle Aged, medicine.disease, Ulcerative colitis, Infliximab, Clinical trial, 030220 oncology & carcinogenesis, Colitis, Ulcerative, Female, 030211 gastroenterology & hepatology, business, medicine.drug
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f0209cb20473cdf82550b9520d983331
https://doi.org/10.1016/s2468-1253(18)30082-7 -
3
المؤلفون: Y. van Megen, A. E. van der Meulen-de Jong, Marie J. Pierik, Joanne P J Bloemsaat-Minekus, Gerard Dijkstra
المصدر: Journal of Crohn's and Colitis. 12:S339-S340
مصطلحات موضوعية: medicine.medical_specialty, business.industry, Gastroenterology, Biosimilar, General Medicine, Interim analysis, Infliximab, Clinical Practice, 03 medical and health sciences, 0302 clinical medicine, 030220 oncology & carcinogenesis, medicine, 030211 gastroenterology & hepatology, Clinical efficacy, Adverse effect, Intensive care medicine, business, medicine.drug
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::586472c9b4c6ba6d71416b5b6b8f12d3
https://doi.org/10.1093/ecco-jcc/jjx180.591 -
4
المؤلفون: Theo Rispens, Geert R. D'Haens, Joanne P J Bloemsaat-Minekus, Anne S. Strik, W. van de Vrie, Y. van Megen
المصدر: Journal of Crohn's and Colitis. 11:S420-S420
مصطلحات موضوعية: medicine.medical_specialty, Crohn's disease, business.industry, Gastroenterology, Biosimilar, General Medicine, Serum concentration, medicine.disease, Infliximab, 03 medical and health sciences, 0302 clinical medicine, 030220 oncology & carcinogenesis, Internal medicine, Medicine, 030211 gastroenterology & hepatology, In patient, business, Prospective cohort study, medicine.drug
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::e92b8c488da5f7a5cd4be8f127107b4e
https://doi.org/10.1093/ecco-jcc/jjx002.789 -
5
المساهمون: Rheumatology, CCA - Innovative therapy
المصدر: Rheumatology, 54, 2, pp. 262-9
Meijs, J, Voskuyl, A E, Bloemsaat-Minekus, J P J & Vonk, M C 2015, ' Blood flow in the hands of a predefined homogeneous systemic sclerosis population: the presence of digital ulcers and the improvement with bosentan ', Rheumatology, vol. 54, no. 2, pp. 262-269 . https://doi.org/10.1093/rheumatology/keu300
Rheumatology, 54(2), 262-269. Oxford University Press
Rheumatology, 54, 262-9مصطلحات موضوعية: Adult, Male, medicine.medical_specialty, Vasodilator Agents, Population, Scars, Systemic scleroderma, Drug Administration Schedule, Rheumatology, Internal medicine, Skin Ulcer, medicine, Humans, Pharmacology (medical), Prospective Studies, education, Aged, education.field_of_study, Analysis of Variance, Sulfonamides, Scleroderma, Systemic, business.industry, Significant difference, Bosentan, Blood flow, Middle Aged, medicine.disease, Hand, Surgery, Treatment Outcome, Homogeneous, Case-Control Studies, Cardiology, Inflammatory diseases Radboud Institute for Health Sciences [Radboudumc 5], Female, medicine.symptom, Laser doppler perfusion imaging, business, medicine.drug
وصف الملف: application/pdf
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01bd01225570b5e73f44f63e4972f49f
https://pubmed.ncbi.nlm.nih.gov/25150178
